Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven recurrent or persistent ovarian, tubal, or
peritoneal carcinoma of the following cell types: Serous adenocarcinoma Mucinous
adenocarcinoma Clear cell adenocarcinoma Transitional cell Endometrioid adenocarcinoma
Undifferentiated carcinoma Mixed epithelial carcinoma Malignant Brenner tumor
Adenocarcinoma not otherwise specified Must not be eligible for any other higher priority
phase II or phase III GOG protocol

PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-2 Life expectancy:
Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3
Granulocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 times normal
SGOT/SGPT/GGT no greater than 2.5 times normal Alkaline phosphatase no greater than 2.5
times normal No acute hepatitis Renal: Creatinine no greater than 2.0 mg/dL Creatinine
clearance greater than 50 mL/min Cardiovascular: LVEF within normal range as determined by
MUGA No congestive heart failure or unstable angina No myocardial infarction within the
past 6 months Prior abnormal cardiac conduction (e.g., bundle branch block, heart block)
allowed if stable for at least 6 months Other: No significant infection No septicemia Body
surface area at least 1 m2 Adequate intestinal function (i.e., does not require IV
hydration or nutritional support) No severe gastrointestinal bleeding No other invasive
malignancies within the past 5 years except nonmelanomatous skin cancer

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy
and recovered Chemotherapy: Must have received at least 1 prior cisplatin-paclitaxel based
regimen At least 3 weeks since prior chemotherapy and recovered No prior anthracycline
therapy Endocrine therapy: At least 3 weeks since prior endocrine therapy and recovered
Radiotherapy: No prior radiotherapy to more than 10% of bone marrow Surgery: At least 3
weeks since prior surgery and recovered